Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01632852 · ClinicalTrials.gov registry record · Phase 1
A Study of CSL362 in Patients With CD123+ Acute Myeloid Leukemia Currently in Remission
A Phase 1 study of Leukemia, Myeloid, Acute, sponsored by CSL Limited.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 5
- Study locations
NCT01632852: Completed Phase 1 study of Leukemia, Myeloid, Acute, sponsored by CSL Limited.
NCT01632852 is a Phase 1 study of Leukemia, Myeloid, Acute that has completed, run by CSL Limited. The registered enrollment target is 30 participants, below the 115-participant average among 30 other Leukemia, Myeloid, Acute trials with a reported enrollment target (74% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01632852, a Phase 1 study of Leukemia, Myeloid, Acute, has completed, sponsored by CSL Limited.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 5
- Study locations
Study Summary
This is a first in human, prospective, multicenter, nonrandomized, open-label, dose-escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and immunogenicity of repeat doses of CSL362.
Primary Outcome
Number of subjects reporting any AEs and the severity of those AEs.
Conditions Studied
Interventions
- BIOLOGICAL CSL362
Study Locations (5)
Illinois
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University Medical School - Chicago
Maryland
- Sidney Kimmel Cancer Center at Johns Hopkins - Baltimore
New York
- Weill Cornell Medical College - New York
Washington
- Seattle Cancer Care Alliance - Seattle
Victoria
- Royal Melbourne Hospital - Parkville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2012-07 |
| Phase | Phase 1 |
What the finished NCT01632852 record still lists
NCT01632852 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 115-participant average among 30 other Leukemia, Myeloid, Acute trials with a reported enrollment target (74% lower).
The record links to 1 condition, with Leukemia, Myeloid, Acute appearing as the primary indexed condition, and to 1 intervention - of which CSL362 is the first listed.
NCT01632852 lists 5 locations in 5 states (Illinois, Maryland, New York).
Frequently Asked Questions
What is clinical trial NCT01632852 about?
NCT01632852 is a clinical study titled "A Study of CSL362 in Patients With CD123+ Acute Myeloid Leukemia Currently in Remission". This is a first in human, prospective, multicenter, nonrandomized, open-label, dose-escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and immunogenicity of repeat doses of CSL362.
What is the current status of trial NCT01632852?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2012-07.
What conditions does trial NCT01632852 study?
This clinical trial studies the following conditions: Leukemia, Myeloid, Acute.
What interventions are being tested in trial NCT01632852?
The interventions under investigation include: CSL362 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01632852?
This trial is sponsored by CSL Limited, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01632852 being conducted?
This trial has 5 study locations across Illinois, Maryland, New York, Washington, Victoria. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leukemia, Myeloid, Acute
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01632852's enrollment target sits among peer trials
30 24th of 30 higher than 6 of 30 other Leukemia, Myeloid, Acute trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Leukemia, Myeloid, Acute trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia
RECRUITING · Phase 1
-
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
RECRUITING · Phase 1
-
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
RECRUITING · Phase 1
-
A Study of DSP-5336 in Relapsed/Refractory AML/ ALL With or Without MLL Rearrangement or NPM1 Mutation
RECRUITING · Phase 1
-
CD33KO-HSPC Infusion Followed by CART-33 Infusion(s) for Refractory/Relapsed AML
RECRUITING · Phase 1
-
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia